Displaying drugs 14751 - 14775 of 14998 in total
RGG0853
RGG0853 is an E1A lipid complex, a repressor gene complexed with a cationic lipid vector.
Investigational
Ozekibart
Ozekibart is a tetravalent recombinant humanized IgG1 agonist antibody targeting the human TRAIL death receptor 5 (DR5). It is being investigated for the treatment of chondrosarcoma.
Investigational
MBP134
MBP134 is a pan-ebolavirus cocktail comprising two broadly neutralizing human antibodies. It is under investigation for the treatment of Sudan ebolavirus (SUDV).
Investigational
EDIT-101
EDIT-101 is a recombinant adeno-associated virus pseudotyped with serotype 5 viral capsid encoding CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats associated protein 9) gene editing constructs.
Investigational
Cellspan Esophageal Implant
The Cellspan Esophageal ImplantTM (CEI) composes of autologous adipose-derived mesenchymal stromal cells (Ad-MSC) seeded onto a polyurethane tubular mesh cell delivery device.
Investigational
ISA101b
ISA101b (peltopepimut-S) is a therapeutic vaccine against the HPV-specific E6/E7 oncoproteins.
Investigational
HH-009
HH-009 is a recombinant human IgG4 monoclonal antibody against FGF19 being studied for the treatment of hepatocellular carcinoma.
Investigational
HTPEP-001
HTPEP-001 is a novel peptide that works to inhibit the activation of transforming growth factor beta (TGF-β). It is being investigated for the treatment of fibrosis.
Investigational
Sacituzumab tirumotecan
Sacituzumab tirumotecan is a recombinant humanized IgG1 anti-TROP2 monoclonal antibody conjugated to a topoisomerase I inhibitor.
Investigational
CRA_10655
Experimental
4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL
Experimental
(3,4-Dihydroxy-Phenyl)-Triphenyl-Arsonium
Experimental
Immucillin-G
Experimental
CRA_10656
Experimental
Fenoxazoline
Experimental
DAS869
Experimental
CG0070
CG0070 is investigated in clinical trials for treating bladder cancer. CG0070 is a solid. CG0070 can potentially destroy cancer cells by two different mechanisms: direct cell killing by the virus and immune-mediated cell killing stimulated by GM-CSF. CG0070, an oncolytic virus therapy with specificity for multiple cancers, has been evaluated...
Investigational
Matched Description: … can potentially destroy cancer cells by two different mechanisms: direct cell killing by the virus and …
Displaying drugs 14751 - 14775 of 14998 in total